AstraZeneca Tops Q2 EPS by 93c, Beats on Revenue
AstraZeneca (NASDAQ:AZN) reported Q2 EPS of $1.72, $0.93 better than the analyst estimate of $0.79. Revenue for the quarter came in at $10.77 billion versus the consensus estimate of $10.51...
Strong Buy
or
AstraZeneca ADR News & Analysis
-
-
AstraZeneca ADR Earnings, Revenue beat In Q2
Investing.com - AstraZeneca (LON:AZN) ADR reported second quarter {{erl-39111||earnings that beat analysts' expectations on Friday and revenue that topped forecasts. The firm reported...
-
Oil Producers, Procter & Gamble, AstraZeneca: 3 Things to Watch
By Liz Moyer Investing.com -- Stocks notched a two-day rally as investors believe the Federal Reserve could slow the pace of interest rate increases after new data showed the economy slowed...
-
Top 5 Things to Watch in Markets in the Week Ahead - Fed Rate Hike, Earnings Flood
By Daniel Shvartsman Investing.com - Central Banks and earnings will continue to dominate the week ahead. After the European Central Bank announced an unexpectedly hawkish 50 basis point...
-
Stellantis, Tesla, AstraZeneca Fall Premarket; Exxon Mobil Rises
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Tuesday, July 5th. Please refresh for updates. Tesla (NASDAQ:TSLA) stock fell 1.4% after the electric car manufacturer...
-
European Stocks Drop; Economic Activity Concerns Weigh
By Peter Nurse Investing.com - European stock markets edged lower Tuesday, with concerns about the region’s economic recovery diluting the positive start to the new month. By 04:20 AM ET...
-
Pharmaceutical Stocks Slide on Worries of Skimmed Down Build Back Better Bill
By Sam Boughedda Shares of pharmaceutical stocks are weaker than the overall market on Tuesday due to investor worries that a skimmed down Build Back Better bill could be introduced,...
-
Big Dividend Payers May Be Next After UK Windfall Tax on Energy
(Bloomberg) -- U.K. Chancellor of the Exchequer Rishi Sunak just slapped a £5 billion ($6.3 billion) levy on energy companies to help fund support for Britons facing a cost-of-living crisis....
-
AstraZeneca Tops Q1 EPS by $1.06
AstraZeneca (NASDAQ:AZN) reported Q1 EPS of $1.89, $1.06 better than the analyst estimate of $0.83. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $10.99...
-
AstraZeneca ADR Earnings, Revenue beat In Q1
Investing.com - AstraZeneca (LON:AZN) ADR reported first quarter {{erl-39111||earnings that beat analysts' expectations on Friday and revenue that topped forecasts. The firm reported...
-
AstraZeneca ADR Earnings, Revenue beat In Q4
Investing.com - AstraZeneca (LON:AZN) ADR reported fourth quarter {{erl-39111||earnings that beat analysts' expectations on Thursday and revenue that topped forecasts. The firm reported...
-
SAP Agrees To Acquire Fintech Firm Taulia
By Sam Boughedda Investing.com — Software firm SAP SE (NYSE:SAP) said Thursday it is in a deal to acquire U.S. fintech company Taulia. SAP said the move to acquire Taulia, a provider of...
-
2021: The Year in Review
By Peter Nurse, Liz Moyer, Sam Boughedda and Yasin Ebrahim Investing.com -- The year 2021 is rapidly drawing to a close, and while it has been a significant improvement, market-wise, to the...
-
AstraZeneca ADR Earnings, Revenue beat In Q3
Investing.com - AstraZeneca (LON:AZN) ADR reported third quarter {{erl-39111||earnings that beat analysts' expectations on Friday and revenue that topped forecasts. The firm reported...
-
Top 5 Things to Watch in Markets in the Week Ahead
By Noreen Burke Investing.com -- Data on inflation will be the highlight of the U.S. economic calendar in the week ahead as investors continue to digest the Federal Reserve’s decision to...
-
Emergent Tanks as U.S. Ends Contract, Vaccine Maker Cuts Outlook
By Dhirendra Tripathi Investing.com – Emergent Biosolutions stock (NYSE:EBS) plunged more than 41% Friday a day after the company said it had agreed to terminate a contract signed in 2012...
-
Valneva Shares Off 12% On Share Offering News
by David Wagner and Daniel Shvartsman French pharmaceutical company Valneva SE ADR (NASDAQ:VALN) shares dropped after announcing a share offering, with shares trading down 12% on the...
-
Valneva Soars as Covid Vaccine Candidate Shows Promise
By Dhirendra Tripathi Investing.com – ADRs of Valneva (NASDAQ:VALN) climbed more than 31% in Monday’s premarket as the company said the phase-3 trials of a prospective vaccine...
-
Novavax Soars on Applying With WHO for Emergency Use of Covid Vaccine
By Dhirendra Tripathi Investing.com – Novavax stock (NASDAQ:NVAX) climbed 9% Thursday after the company applied with the World Health Organization for emergency approval to its...
-
AstraZeneca Gets a Boost from U.S. Travel Rules Tweak, Breast Cancer Drug Trial
By Dhirendra Tripathi Investing.com – AstraZeneca (LON:AZN) ADRs (NASDAQ:AZN) traded 1% higher in Tuesday’s premarket as the proposed changes to rules governing travel to the U.S. will...
-
Novavax Slips on Report India Launch May Take More Time
By Dhirendra Tripathi Investing.com – Novavax stock (NASDAQ:NVAX) fell 4.2% on Thursday on a report in India’s Economic Times newspaper that the launch of the company’s Covid-19 vaccine...
-
European Airlines Weaker As EU, U.S. Try to Limit Transatlantic Travel
By Dhirendra Tripathi Investing.com – Stocks of most European airlines traded lower Tuesday as the EU dropped the U.S. from its ‘safe travel list’ and the latter, for its...
-
Fed Rattles Global Markets; Jobless Claims; Auto Chip Woe - What's Moving Market
By Geoffrey Smith Investing.com -- Global markets tumble and U.S. stocks are set to extend losses after the Federal Reserve's latest minutes suggested it will start reducing its bond...
-
ASX 200 Closes Flat As Earnings Roll On
By Oliver Gray Investing.com - The S&P/ASX 200 was little changed at 7509.9 on Wednesday, following declines of 0.94% in the previous session as mining stocks weighed down the market as...
-
Australian Shares Gain In Early Trade
By Oliver Gray Investing.com - The S&P/ASX 200 added 17.4 points or 0.23% 7528.4 on Wednesday, following declines of 0.94% in the previous session, with market participants proving...
-
FTSE 100 to Lose Second-Biggest Name as BHP Goes Home
(Bloomberg) -- The U.K.’s blue-chip FTSE 100 Index will lose its second-biggest stock by market value and the world’s biggest mining company, after BHP Group (NYSE:BHP) announced plans to...
-
AstraZeneca ADR Earnings, Revenue beat In Q2
Investing.com - AstraZeneca (LON:AZN) ADR reported second quarter {{erl-39111||earnings that beat analysts' expectations on Thursday and revenue that topped forecasts. The firm reported...
-
FibroGen Plunges As FDA Panel Rejects Drug For Anemia Linked To Kidney Disease
By Dhirendra Tripathi Investing.com – FibroGen (NASDAQ:FGEN) stock slumped 44% Friday as an advisory committee of the Food and Drug Administration rejected the company’s proposed inhibitor...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
